<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR15">
 <label>15.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>List</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Beran</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>DiPersio</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Slack</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Vey</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>Rosenfeld</surname>
    <given-names>CS</given-names>
   </name>
   <name>
    <surname>Greenberg</surname>
    <given-names>P</given-names>
   </name>
  </person-group>
  <article-title>Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes</article-title>
  <source>Leukemia</source>
  <year>2003</year>
  <volume>17</volume>
  <issue>8</issue>
  <fpage>1499</fpage>
  <lpage>1507</lpage>
  <pub-id pub-id-type="doi">10.1038/sj.leu.2403021</pub-id>
  <?supplied-pmid 12886236?>
  <pub-id pub-id-type="pmid">12886236</pub-id>
 </element-citation>
</ref>
